Researchers have identified and validated two DNA methylation markers that could help physicians to more accurately determine a patient’s response to epigenetic drugs for treatment of myelodysplastic syndromes (MDS), new research suggests.
Researchers have identified and validated two DNA methylation markers that could help physicians to more accurately determine a patient’s response to epigenetic drugs for treatment of myelodysplastic syndromes (MDS), new research suggests.